Microinflammation in the pathogenesis of diabetic nephropathy

Journal of Diabetes Investigation

Volumn 4, Issue 2, 2013, Pages 142-149

  Shikata, Kenichi ^a,b   Makino, Hirofumi ^a,b  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Inflammation; Microinflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHOLECYSTOKININ OCTAPEPTIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EXENDIN 4; FRACTALKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; L SELECTIN; LIRAGLUTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PENTOXIFYLLINE; PIOGLITAZONE; POLYOL; PROTEIN KINASE C; RANTES; SCAVENGER RECEPTOR A; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; DIABETIC NEPHROPATHY; DIABETOGENESIS; ENZYME ACTIVATION; GLOMERULUS FILTRATION; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; MICROINFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REVIEW;

EID: 84878371278     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12050     Document Type: Review

References (80)

1. Magee GM, Bilous RW, Cardwell CR, et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52: 691-697.
2. Zemin C, Mark EC. Pathogenesis of diabetic nephropathy. J Diabetes Invest 2011; 2: 243-247.
3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
4. Koya D, Jirousek MR, Lin YW. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-126.
5. Ziyadeh FN, Sharma K, Ericksen M, et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93: 536-542.
6. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340.
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 14: 115-126.
8. Furuta T, Saito T, Ootaka T, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21: 480-485.
9. Shikata K, Makino H. Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol 2001; 134: 46-54.
10. Staunton DE, Marlin SD, Stratowa C, et al. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 1988; 52: 925-933.
11. Sumagin R, Sarelius IH. TNF α activation of arterioles and venules alters distribution and levels of ICAM 1 and affects leukocyte-endothelial cell interactions. Am J Physiol Heart Circ Physiol 2006; 291: H2116-H2125.
12. Sucosky P, Balachandran K, Elhammali A, et al. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-β1-dependent pathway. Arterioscler Thromb Vasc Biol 2009; 29: 254-260.
13. Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1: 447-456.
14. Sugimoto H, Shikata K, Hirata K, et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes, 1997; 46: 2075-2081.
15. Coimbra TM, Janssen U, Gröne HJ, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167-182.
16. Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-2593.
17. Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005; 16: 1711-1722.
18. Clausen P, Jacobsen P, Rossing K, et al. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med 2000; 17: 644-649.
19. Lin J, Glynn RJ, Rifai N, et al. Inflammation and progressive nephropathy in type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2008; 31: 2338-2343.
20. Ina K, Kitamura H, Okeda T, et al. Vascular cell adhesion molecule-1 expression in the renal interstitium of diabetic KKAy mice. Diabetes Res Clin Pract 1999; 44: 1-8.
21. Rubio-Guerra AF, Vargas-Robles H, Lozano JJ, et al. Correlation between circulating adhesion molecule levels and albuminuria in type-2 diabetic hypertensive patients. Kidney Blood Press Res 2009; 32: 106-109.
22. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes, 2002; 51: 1157-1165.
23. Hara T, Ishida T, Cangara HM, et al. Endothelial cell-selective adhesion molecule regulates albuminuria in diabetic nephropathy. Microvasc Res 2009; 77: 348-355.
24. Narumi S, Onozato ML, Tojo A, et al. Tissue-specific induction of E-selectin in glomeruli is augmented following diabetes mellitus. Nephron 2001; 89: 161-171.
25. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, et al. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in type 1 diabetic patients. J Diabetes Complications 2006; 20: 188-195.
26. Ogawa D, Shikata K, Honke K, et al. Cerebroside sulfotransferase deficiency ameliorates L-selectin-dependent monocyte infiltration in the kidney after ureteral obstruction. J Biol Chem 2004; 16: 2085-2090.
27. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-296.
28. de Winther MP, van Dijk KW, Havekes LM, et al. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 290-297.
29. Usui HK, Shikata K, Sasaki M. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007; 56: 363-372.
30. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008; 13: 944-955.
31. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 368-377.
32. Wada T, Furuichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58: 1492-1498.
33. Panzer U, Steinmetz OM, Stahl RA, et al. Kidney diseases and chemokines. Curr Drug Targets 2006; 7: 65-80.
34. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003; 26: 2421-2425.
35. Chow Y, Nikolic-Paterson DJ, Ozols E, et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80.
36. Kitagawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237-246.
37. Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
38. Kikuchi Y, Ikee R, Hemmi N, et al. Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol 2004; 97: e17-e25.
39. Kikuchi Y, Imakiire T, Hyodo T, et al. Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli. Nephrol Dial Transplant 2005; 20: 2690-2696.
40. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001; 22: 83-87.
41. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-2512.
42. Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012.
43. DiPetrillo K, Coutermarsh B, Gesek FA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003; 284: F113-F121.
44. Bertani T, Abbate M, Zoja C, et al. Tumor necrosis factor induces glomerular damage in rabbit. Am J Pathol 1989; 134: 419-430.
45. Baud L, Perez J, Friedlander G, et al. Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett 1998; 239: 50-54.
46. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1938; 141: 2629-2634.
47. McCarthy ET, Sharma R, Sharma M, et al. TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998; 9: 433-438.
48. Sugimoto H, Shikata K, Wada J, et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible oxide synthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-886.
49. Navarro JF, Milena FJ, Mora C, et al. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006; 26: 562-570.
50. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005; 20: 2601-2604.
51. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
52. Navarro JF, Mora C, Macía M. Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 53-61.
53. Kajitani N, Shikata K, Nakamura A, et al. Microinflammation is a common risk factor for progression of nephropathy and atherosclerosis in Japanese patients with type 2 diabetes Diabetes Res Clin Pract 2010; 88: 171-176.
54. Sassy-Prigent C, Heudes D, Mandet C, et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49: 466-475.
55. Pfeilschifter J, Pignat W, Vosbeck K, et al. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun 1989; 159: 385-394.
56. Dai SM, Matsuno H, Nakamura H, et al. Interleukin-18 enhances monocyte tumor necrosis factor α and interleukin-1β production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 2004; 50: 432-443.
57. Mariño E, Cardier JE. Differential effects of IL-18 on endothelial cell apoptosis mediated by TNF-α and Fas (CD59). Cytokine 2003; 22: 142-148.
58. Nakamura A, Shikata K, Hiramatsu M, et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895.
59. Araki S, Haneda M, Koya D, et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 2007; 50: 867-873.
60. Suzuki D, Miyazaki M, Naka R, et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995; 44: 1233-1238.
61. Sekizuka K, Tomino Y, Sei C, et al. Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 1994; 68: 284-285.
62. Utimura R, Fujihara CK, Mattar AL. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209-216.
63. Rodríguez-Iturbe B, Quiroz Y, Shahkarami A, et al. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 2005; 68: 1041-1047.
64. Yozai K, Shikata K, Sasaki M, et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005; 16: 3326-3338.
65. Lee FT, Cao Z, Long DM, et al. Interactions between angiotensin II and NF-κB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004; 15: 2139-2151.
66. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
67. Usui H, Shikata K, Matsuda M, et. al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003; 18: 265-272.
68. Ota T, Takamura T, Ando H, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-851.
69. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292: F1141-F1150.
70. Han J, Thompson P, Beutler D. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-394.
71. DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 2004; 24: 352-359.
72. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra JR, et al. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 1995; 43: 116-121.
73. Navarro JF, Mora C. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy. Diabetes Care 1999; 22: 1006-1008.
74. Miyamoto S, Shikata K, Miyasaka K, et al. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 2012; 61: 897-907.
75. Bullock BP, Heller RS, Habener JF, et al. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
76. Schlatter P, Beglinger C, Drewe J, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141: 120-128.
77. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
78. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
79. Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61: 1422-1434.
80. Tone A, Shikata K, Sasaki M, et al. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 2005; 48: 2402-2411.